“The other level is bioprocessing, where seeing better than high single-digit growth for the year with equipment potentially accelerating or even consumables accelerating more as we see more biosimilars and mAb production increasing.”

In context

“sistent with 2025. This is how we are setting up the year based on these improving end markets and some of the momentum that we saw coming out of Q4. Now, Mike, to your point, as to upside levers, there's probably two larger drivers that are most relevant there. One is to see continued improvement across our life science end markets. We are seeing some of that. We want to see more of that, especially some of those policy headwinds that we are seeing here in the U.S. in particular. We would like to see that improved biotech funding environment fall through now to an increasing order book in that particular segment. So encouraged, but we do not see that yet. Then, of course, China continuing an acceleration in life science research would be helpful in those life science end markets as well. The other level is bioprocessing, where seeing better than high single-digit growth for the year with equipment potentially accelerating or even consumables accelerating more as we see more biosimilars and mAb production increasing. Those would be two areas that could produce additional upside to the guide. Michael Ryskin: Okay. That is helpful. If I could follow-up just on the bioprocessing outlook for 2026. Can you talk a little bit about the order book, maybe book to bill, how that shaped up in the fourth quarter? For consumables and for equipment? Just give us a little bit more clarity on the confidence that's driving that '26 outlook. You know, you still have easy comps and equipment, but a little bit tougher comps in consumables. So for both the equipment and the consumable side, what did the orders look like exiting the year and how that supports next year's outlook? Rainer Blair: Sure. The order book fully supports the high single-digit growth that we have been talking about for 2026. As you know, the lead ti”